Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Operating Income of $2.16 billion for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $2.16B | +811.9% |
| 2024 | -$303.00M | -170.0% |
| 2023 | $433.00M | +119.7% |
| 2022 | -$2.20B | -228.0% |
| 2021 | $1.72B | +148.0% |
| 2020 | -$3.57B | -706.3% |
| 2019 | -$443.00M | +72.9% |
| 2018 | -$1.64B | +90.6% |
| 2017 | -$17.48B | -911.7% |
| 2016 | $2.15B | -35.7% |
| 2015 | $3.35B | -15.2% |
| 2014 | $3.95B | +139.6% |
| 2013 | $1.65B | -25.2% |
| 2012 | $2.21B | -29.1% |
| 2011 | $3.11B | -19.7% |
| 2010 | $3.87B | +61.0% |
| 2009 | $2.40B | +110.0% |
| 2008 | $1.15B | -52.2% |
| 2007 | $2.40B | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $882.00M | +1829.4% | +93.8% |
| June 30, 2025 | $455.00M | +9200.0% | -12.3% |
| March 31, 2025 | $519.00M | +338.1% | +1117.6% |
| September 30, 2024 | -$51.00M | -114.8% | -920.0% |
| June 30, 2024 | -$5.00M | +99.2% | +97.7% |
| March 31, 2024 | -$218.00M | -1576.9% | -163.4% |
| September 30, 2023 | $344.00M | -17.9% | +152.6% |
| June 30, 2023 | -$654.00M | +31.1% | -4930.8% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +811.9% in Operating Income compared to the prior fiscal year.
- Over the 2007–2025 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s operating income has declined by 9.9% (from $2.40 billion to $2.16 billion).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: